- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05712811
Comparison of Cryotherapy and Peeling Agent in the Treatment of Common Warts
January 26, 2023 updated by: Dr kiran gul, Combined Military Hospital Abbottabad
Cryotherapy Versus Topical Tricholoacetic Acid 90% in Treatment of Common Warts
Objective: To compare the efficacy of cryotherapy using liquid nitrogen (cryoget method) versus trichloroacetic acid 90% (applicator method) in treatment of common warts.
Study Design: Randomized Control Trial. Place And Duration of Study: Department of Dermatology, CMH Abbottabad from Jun 2022 to Nov, 2022.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
A total of 60 patients were enrolled in this investigation by non-probability consecutive sampling technique.
Sample size was calculated using WHO sample size calculator and patients were randomized into two equal groups, A and B, each comprising of 30 patients through lottery method.
Patients with common warts such as hard lesions, raised lumps with rough surfaces at the back of their fingers, around nails and palm of their hands between the ages of 18 and 60 were included, whereas those with genital warts, cardiac, hepatic, renal, or hypercholesterolemia were excluded.
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Kpk
-
Abbottābād, Kpk, Pakistan, 22010
- CMH Abbottabad
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patient presented with common warts in dermatology opd
Exclusion Criteria:
• Patients with warts on toes and tip of fingers
- genital warts
- cardiac, hepatic and renal disease
- hypercholesterolemia
- hypersensitivity reactions
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: Group A cryotherapy
Cryotherapy Group A had their warts treated once every two weeks for a total of twelve weeks, with liquid nitrogen using cryoget method for 10 to 15 seconds on each lesion (depending on size, until a narrow white rim of around 1 mm developed around it).
|
Group A had their warts treated once every two weeks for a total of twelve weeks, with liquid nitrogen using cryoget method for 10 to 15 seconds on each lesion (depending on size, until a narrow white rim of around 1 mm developed around it).
Other Names:
|
|
ACTIVE_COMPARATOR: Group B Topical TCA 90%
Topical TCA 90 % Warts in Group B were treated with liquid TCA 90% by an applicator every two weeks for a total of twelve weeks.
After 20 minutes, patients were instructed to remove the solution by washing their warts with water or regular saline
|
Group B were treated with liquid TCA 90% by an applicator every two weeks for a total of twelve weeks.
After 20 minutes, patients were instructed to remove the solution by washing their warts with water or regular saline.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Comparison of cryotherapy and Tricholoracetic acid 90% in treatment of common warts
Time Frame: 12 weeks
|
Outcome was determined at the end of third month and the patients were labelled as cured and the efficacy was labelled as "Yes" in cases with absence of all the lesions.
After twelve weeks of therapy, individuals with persistent warts were regarded as cases of treatment failure and efficacy was labelled as "No".
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
June 1, 2022
Primary Completion (ACTUAL)
November 30, 2022
Study Completion (ACTUAL)
November 30, 2022
Study Registration Dates
First Submitted
January 18, 2023
First Submitted That Met QC Criteria
January 26, 2023
First Posted (ACTUAL)
February 6, 2023
Study Record Updates
Last Update Posted (ACTUAL)
February 6, 2023
Last Update Submitted That Met QC Criteria
January 26, 2023
Last Verified
January 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CMHAbbottabad
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Warts
-
RXi Pharmaceuticals, Corp.UnknownPlantar Warts | Common Warts | HPV (Human Papillomavirus) | Periungual WartsUnited States
-
Cairo UniversityNot yet recruitingPlantar Warts Treatment
-
Riphah International UniversityRecruitingPlantar Wart | Wart | Common Wart | Warts Hand | Flat Wart | Viral Wart | Common Warts (Verruca Vulgaris) | Warts of FootPakistan
-
Verrica Pharmaceuticals Inc.CMIC Co, Ltd. Japan; Medidata Solutions; Veeva Systems; Canfield Scientific Inc.; Torii Pharmaceutical Co. Ltd... and other collaboratorsNot yet recruitingWarts | Human Papilloma Virus (HPV) | Common Warts | Common Warts (Verruca Vulgaris)United States
-
Verrica Pharmaceuticals Inc.CMIC Co, Ltd. Japan; Medidata Solutions; Veeva Systems; Canfield Scientific Inc.; Allucent (US) LLC and other collaboratorsRecruitingWarts | Human Papilloma Virus (HPV) | Common Warts | Common Warts (Verruca Vulgaris)United States
-
Verrica Pharmaceuticals Inc.Medidata Solutions; Veeva Systems; Canfield Scientific Inc.; Torii Pharmaceutical... and other collaboratorsRecruitingWarts | Human Papilloma Virus (HPV) | Common Warts | Common Warts (Verruca Vulgaris)United States
-
Benha UniversityCompletedCutaneous Warts | Human Papilloma Virus (HPV)Egypt
-
Maruho Co., Ltd.CompletedCutaneous Common WartsUnited States
-
Maruho Co., Ltd.CompletedCutaneous Common WartsUnited States
-
Karo Pharma ABCompletedPlantar Wart | Common WartPoland
Clinical Trials on CRYOTHERAPY
-
University Hospital, LilleAlmirall, SASNot yet recruiting
-
Weill Medical College of Cornell UniversityProstate Cancer FoundationRecruiting
-
Azienda Ospedaliera San Camillo ForlaniniCompleted
-
Hanyang University Seoul HospitalCompletedCryotherapy EffectKorea, Republic of
-
Cairo UniversityNot yet recruiting
-
Creighton UniversityCompleted
-
Chung Shan Medical UniversityCompleted
-
Ondokuz Mayıs UniversityCompletedPain, Postoperative | Pulpitis | Caries; DentinTurkey (Türkiye)
-
Jonsson Comprehensive Cancer CenterCompletedProstate Cancer | Prostate Adenocarcinoma | Prostate DiseaseUnited States
-
CSA Medical, Inc.WithdrawnLung Diseases, Obstructive | Airway Obstruction | Lung Disease Airways | Airway; Obstruction, With Emphysema